BD's $19 billion U.S. manufacturing pact trades domestic production for relief from future medtech tariffs
The maker of syringes, needles and infusion pumps will expand U.S. output and use American steel for needles in exchange for conditional Section 232 relief. Hospital and health system buyers should expect more deals like it.
Article summary
- Why it matters: The Section 232 investigation into medical devices has not produced tariffs yet, but suppliers are already negotiating their way out of them. BD’s agreement shows the template: invest in U.S. capacity, commit to domestic inputs, and receive conditional tariff relief. For health system procurement, supplier-specific deals will create uneven landed costs across otherwise similar products.
- What to do first: Ask every medtech supplier about Section 232. Request their exposure by product and country of origin, any relief agreements, and how they would pass through tariffs.
- Review price-adjustment clauses. Make sure tariff pass-throughs require documentation and apply only to affected products and origins.
- $19B
- BD's planned U.S. investment over several years
- ~80%
- target share of BD's essential medtech supplied domestically
- ~5B
- additional essential medical consumables per year from U.S. sites
- Sept. 2025
- when the Section 232 medtech inquiry opened
On this page
The details
BD, which calls itself the largest U.S. manufacturer of essential medical consumables, announced a partnership with the administration on Oct. 6. Under it, BD will:
- Invest a total of $19 billion in the U.S. over several years in manufacturing, innovation and production capabilities
- Spend $3 billion expanding strategic production sites
- Raise annual U.S. output by about 5 billion essential medical consumables
- Make all U.S.-used needles with American-made steel
- Increase its share of domestically supplied essential medical technology to about 80%
In return, BD products receive relief from any future Section 232 tariffs, subject to undisclosed milestones. BD has not quantified the financial impact because final rates and covered products aren’t set.
The Section 232 investigation into medical equipment and device imports began in September 2025. More than a year later, no device-specific tariffs have been announced. BD said it will give more detail on the financial impact once rates are final. “The administration recognizes the importance of investing in a stronger, more secure healthcare supply chain,” CEO Tom Polen said.
BD’s U.S. network includes sites in Columbus and Broken Bow, Nebraska; Canaan, Connecticut; Añasco, Puerto Rico; Sandy, Utah; El Paso, Texas; Covington, Georgia; and Sumter, South Carolina.
What the money covers. BD said the $19 billion covers capital, operational and supply chain spending over several years; the $3 billion for strategic production sites is part of that total. It did not give a breakdown by site or job numbers. BD says the consumables involved are used in about 90% of U.S. hospital visits, and that it has more than 60,000 employees worldwide.
How the relief works. Relief applies to covered BD products and inputs and depends on the final scope of any future Section 232 action and on BD meeting agreed milestones, according to the company’s release. That means the value of the deal to BD, and to its customers, can’t be calculated until the government sets device tariffs.
Track record. BD points to its history in U.S. health care, including developing the first disposable syringe and delivering more than two billion additional devices during the pandemic.
How supplier-specific relief changes a bid evaluation
When one supplier has tariff relief and another doesn’t, the lowest quote may not be the lowest landed cost. Take two suppliers of the same consumable:
| Supplier A (U.S.-made, with relief) | Supplier B (imported) | |
|---|---|---|
| Quoted price per case | $100 | $90 |
| Landed cost with no device tariff | $100 | $90 |
| Landed cost at a 10% tariff | $100 | $99 |
| Landed cost at a 25% tariff | $100 | $112.50 |
The tariff rates are hypothetical; no device rates have been set. By our calculation, Supplier B stays cheaper only while the tariff is below about 11%. Above that, the relief agreement is worth more than the 10% price gap. Health system teams awarding 2027 contracts can model this now and write award terms that let them shift volume if tariffs are announced mid-contract.
Where the device investigation stands
| Date | Step |
|---|---|
| September 2025 | Section 232 investigation into medical equipment and device imports begins |
| Oct. 6, 2026 | BD announces its partnership and conditional relief |
| Not yet set | Final device tariff rates and covered products |
Until rates are set, relief agreements like BD’s are a promise about future cost, not a current saving.
What it means by category
| Category | Exposure | Our read |
|---|---|---|
| Syringes and needles | High volume, much imported | BD’s relief and U.S. steel commitment favor it in 2027 awards if tariffs land |
| Infusion pumps and sets | Mixed domestic and imported supply | Ask each supplier for origin by SKU |
| Gloves, gowns and other PPE | Heavily imported | Likely most exposed if device tariffs include PPE |
| Specialty devices | Smaller volumes, fewer suppliers | Fewer alternatives, so pass-through risk is higher |
This is our assessment, not a forecast of final rates.
Questions to ask your medtech suppliers
- What share of the products we buy is made in the U.S., and where is the rest made?
- Are you negotiating a relief agreement, and what milestones would it require?
- If tariffs apply, which SKUs would be affected and by how much?
- Will you commit to documented, product-specific pass-through rather than across-the-board increases?
- What is your capacity plan if demand shifts to U.S.-made products?
What procurement teams should do
- Ask every medtech supplier about Section 232. Request their exposure by product and country of origin, any relief agreements, and how they would pass through tariffs.
- Review price-adjustment clauses. Make sure tariff pass-throughs require documentation and apply only to affected products and origins.
- Factor domestic capacity into sourcing. Suppliers with U.S. production and relief agreements may carry lower tariff risk. Weigh that alongside unit price in 2027 awards.
- Watch for the final rule. When Section 232 device tariffs are announced, re-run landed-cost models for every category that relies on imported consumables.
What to watch next
- Section 232 on medical devices. Final rates and covered products are not set; BD’s relief depends on milestones that have not been disclosed.
- Copycat agreements. Other medtech suppliers may negotiate similar deals, which would split the market into tariff-protected and exposed suppliers.
- Capacity timelines. Ask when the extra 5 billion units a year actually reach your product lines.
The bigger picture
Health systems have been here before: PPE shortages in 2020 showed how concentrated sourcing for low-cost consumables can fail. The administration is using tariff threats and relief deals to pull production onshore, as it did in pharmaceuticals. Medical consumables are next. Procurement teams in healthcare should expect a two-tier market: suppliers with relief deals and U.S. capacity, and those without, priced accordingly once tariffs land.
Questions procurement teams are asking
Are there Section 232 tariffs on medical devices?
Not yet. The administration opened a Section 232 inquiry into medical devices and equipment in September 2025, but as of BD's announcement no device-specific tariffs had been set.
What does BD's deal mean for hospital procurement?
BD products are positioned for relief from future Section 232 tariffs if BD hits undisclosed milestones. Health systems should ask other medtech suppliers whether they are pursuing similar agreements and how tariffs would be passed through.
What did BD agree with the U.S. government?
BD will invest $19 billion in the U.S. over several years, including $3 billion to expand strategic production sites, raise U.S. output by about 5 billion consumables a year and use American-made steel for U.S. needles. In return, its products get relief from future Section 232 device tariffs, subject to milestones.
Are there Section 232 tariffs on medical devices?
Not yet. The investigation began in September 2025, and no device-specific rates or covered products had been announced as of October 2026.
How we reported this
This story draws on 3 sources, listed below, and reflects figures as reported on October 14, 2026. The sections on why it matters and what procurement teams should do are Procurement Signal analysis. It is not legal or financial advice. See our editorial standards.
